Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Biliary Tract Diseases

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 150 articles:
HTML format
Text format



Single Articles


    July 2017
  1. GU J, Jeong S, Xia Q
    Intrahepatic cholangiocarcinoma arising from HBV Infection may be a highly selected population for liver transplantation.
    Hepatology. 2017 Jul 31. doi: 10.1002/hep.29413.
    PubMed     Text format    


  2. THOMPSON MD, Moghe A, Cornuet P, Marino R, et al
    beta-catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29371.
    PubMed     Text format     Abstract available


  3. PURI P, Daita K, Joyce A, Mirshahi F, et al
    The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Hepatology. 2017 Jul 11. doi: 10.1002/hep.29359.
    PubMed     Text format     Abstract available


  4. PELLAT A, Vaquero J, Fouassier L
    Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.
    Hepatology. 2017 Jul 3. doi: 10.1002/hep.29350.
    PubMed     Text format     Abstract available


    June 2017
  5. WANG DQ, Portincasa P, Tso P
    Transintestinal cholesterol excretion (TICE): A secondary, non-biliary pathway contributing to reverse cholesterol transport.
    Hepatology. 2017 Jun 27. doi: 10.1002/hep.29341.
    PubMed     Text format    


  6. DAWSON PA
    Hepatic bile acid uptake in humans and mice: Multiple pathways and expanding potential role for gut-liver signaling.
    Hepatology. 2017 Jun 23. doi: 10.1002/hep.29325.
    PubMed     Text format    


  7. ALVARO D
    The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles?
    Hepatology. 2017 Jun 12. doi: 10.1002/hep.29314.
    PubMed     Text format    


  8. CHOI TY, Khaliq M, Tsurusaki S, Ninov N, et al
    Bmp Signaling Governs Biliary-Driven Liver Regeneration in Zebrafish via Tbx2b and Id2a.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29309.
    PubMed     Text format     Abstract available


  9. LIBERAL R, Grant CR, Yuksel M, Graham J, et al
    Treg Conditioning Endows Activated Teff with Suppressor Function in Autoimmune Hepatitis/Autoimmune Sclerosing Cholangitis.
    Hepatology. 2017 Jun 9. doi: 10.1002/hep.29307.
    PubMed     Text format     Abstract available


  10. QIAN Y, Yao W, Yang T, Yang Y, et al
    aPKC-iota/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.
    Hepatology. 2017 Jun 2. doi: 10.1002/hep.29296.
    PubMed     Text format     Abstract available


    May 2017
  11. ARBELAIZ A, Azkargorta M, Krawczyk M, Santos-Laso A, et al
    Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Hepatology. 2017 May 26. doi: 10.1002/hep.29291.
    PubMed     Text format     Abstract available


  12. CHIANG JYL
    Linking long non-coding RNA to control bile acid signaling and cholestatic liver fibrosis.
    Hepatology. 2017 May 24. doi: 10.1002/hep.29289.
    PubMed     Text format    


  13. TOMINAGA K, Kamimura K, Sakamaki A, Terai S, et al
    Intraductal Papillary Neoplasm of the Bile Duct: A Rare Liver Tumor Complicated by Malignancy.
    Hepatology. 2017 May 18. doi: 10.1002/hep.29266.
    PubMed     Text format    


  14. GUO GL
    Why are females more susceptible to cholestasis-induced liver injury - Could it be LncRNA H19?
    Hepatology. 2017 May 15. doi: 10.1002/hep.29255.
    PubMed     Text format    


  15. SLIJEPCEVIC D, Roscam Abbing RLP, Katafuchi T, Blank A, et al
    Hepatic uptake of conjugated bile acids is mediated by both NTCP and OATPs and modulated by intestinal sensing of plasma bile acid levels in mice.
    Hepatology. 2017 May 12. doi: 10.1002/hep.29251.
    PubMed     Text format     Abstract available


  16. TANAKA T, Zhang W, Sun Y, Shuai Z, et al
    Autoreactive Monoclonal Antibodies from Patients with Primary Biliary Cholangitis Recognize Environmental Xenobiotics.
    Hepatology. 2017 May 3. doi: 10.1002/hep.29245.
    PubMed     Text format     Abstract available


    April 2017
  17. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Text format     Abstract available


  18. MIELI-VERGANI G, Vergani D
    The riddle of juvenile sclerosing cholangitis.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29208.
    PubMed     Text format    


  19. DENEAU MR, El-Matary W, Valentino PL, Abdou R, et al
    The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.
    Hepatology. 2017 Apr 8. doi: 10.1002/hep.29204.
    PubMed     Text format     Abstract available


    March 2017
  20. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Text format     Abstract available


  21. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Text format     Abstract available


    February 2017
  22. LI H, Zhou ZQ, Yang ZR, Tong DN, et al
    MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
    Hepatology. 2017 Feb 14. doi: 10.1002/hep.29116.
    PubMed     Text format     Abstract available


  23. KRAWCZYK M, Rau M, Grunhage F, Schattenberg JM, et al
    The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm.
    Hepatology. 2017 Feb 8. doi: 10.1002/hep.29100.
    PubMed     Text format    


    January 2017
  24. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Text format     Abstract available


  25. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Text format     Abstract available


  26. SHUAI Z, Wang J, Badamagunta M, Choi J, et al
    The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29059.
    PubMed     Text format     Abstract available


  27. BJORNSSON ES, Jonasson JG
    Idiosyncratic drug-induced liver injury associated with bile duct loss and vanishing bile duct syndrome: Rare but has severe consequences.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29040.
    PubMed     Text format    


  28. VIVEIROS A, Reiterer M, Schaefer B, Finkenstedt A, et al
    CCBE1 Mutation causing Sclerosing Cholangitis - Expanding the Spectrum of Lymphedema-Cholestasis Syndrome.
    Hepatology. 2017 Jan 10. doi: 10.1002/hep.29037.
    PubMed     Text format    


  29. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Text format     Abstract available


    December 2016
  30. WANG KS, Tiao G, Bass LM, Hertel PM, et al
    Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29019.
    PubMed     Text format     Abstract available


  31. HAUSSINGER D, Keitel V
    Dual role of the bile acid receptor TGR5 for hepatic lipid metabolism in feast and famine.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29017.
    PubMed     Text format    


  32. QIU YL, Gong JY, Feng JY, Wang RX, et al
    Defects in MYO5B are associated with a spectrum of previously undiagnosed low gamma-glutamyltransferase cholestasis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29020.
    PubMed     Text format     Abstract available


  33. BRANDI G, De Lorenzo S, Palloni A, Biasco G, et al
    Aspirin for cholangiocarcinoma prevention: new targets to shift the dogma from ascertained risk to possible prevention (Reply to: Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma).
    Hepatology. 2016 Dec 23. doi: 10.1002/hep.28999.
    PubMed     Text format    


  34. TRAUNER M, Fuchs CD, Halilbasic E, Paumgartner G, et al
    New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28991.
    PubMed     Text format     Abstract available


  35. GUPTA R, Gupta J
    Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28994.
    PubMed     Text format    


  36. SAPISOCHIN G, Bruix J
    In response to: Strategies to improve survival of patients with intrahepatic cholangiocarcinoma undergoing liver transplantation.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28993.
    PubMed     Text format    


  37. FAN W, Yang H, Liu T, Wang J, et al
    Prohibitin 1 Suppresses Liver Cancers Tumorigenesis in Mice and Human Hepatocellular and Cholangiocarcinoma cells.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28964.
    PubMed     Text format     Abstract available


  38. BONKOVSKY HL, Kleiner DE, Gu J, Odin JA, et al
    Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28967.
    PubMed     Text format     Abstract available


  39. JANSEN PL, Ghallab A, Vartak N, Reif R, et al
    The ascending pathophysiology of cholestatic liver disease.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28965.
    PubMed     Text format     Abstract available


    November 2016
  40. DE VRIES EM, de Krijger M, Farkkila M, Arola J, et al
    Validation of the Prognostic Value of Histologic Scoring Systems in Primary Sclerosing Cholangitis; An International Cohort Study.
    Hepatology. 2016 Nov 23. doi: 10.1002/hep.28963.
    PubMed     Text format     Abstract available


  41. MOHANTY SK, Donnelly B, Lobeck I, Walther A, et al
    The SRL peptide of Rhesus Rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.
    Hepatology. 2016 Nov 17. doi: 10.1002/hep.28947.
    PubMed     Text format     Abstract available


  42. SAMUR S, Klebanoff M, Banken R, Pratt DS, et al
    Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28932.
    PubMed     Text format     Abstract available


  43. GRADILONE SA
    Extracellular vesicles as therapeutic carriers of microRNAs for cholangiocarcinoma.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28925.
    PubMed     Text format    


  44. ALTAII H, Al-Kindi SG, Oliveira GH, Yaqoob Z, et al
    Aspirin use and risk of cholangiocarcinoma: External validation with big data.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28920.
    PubMed     Text format    


  45. YAN S, Tang J, Zhang Y, Wang Y, et al
    Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3-mediated hepatocyte nuclear receptor 4alpha/cholesterol 7alpha-hydroxylase pathway in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28928.
    PubMed     Text format     Abstract available


    October 2016
  46. DESAI M, Mathur B, Eblimit Z, Vasquez H, et al
    Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28890.
    PubMed     Text format     Abstract available


  47. ZHANG L, Yang Z, Trottier J, Barbier O, et al
    LncRNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate Shp mRNA decay.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28882.
    PubMed     Text format     Abstract available


    September 2016
  48. DAHLQVIST G, Gaouar F, Carrat F, Meurisse S, et al
    Large-scale characterization study of patients with antimitochondrial antibodies but non-established primary biliary cholangitis.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28859.
    PubMed     Text format     Abstract available


  49. LAGES CS, Simmons J, Maddox A, Jones K, et al
    The dendritic cell-Th17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28851.
    PubMed     Text format     Abstract available


  50. KULKARNI SR, Soroka CJ, Hagey LR, Boyer JL, et al
    Sirtuin 1 activation alleviates cholestatic liver injury in a cholic acid fed mouse model of cholestasis.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28826.
    PubMed     Text format     Abstract available


  51. MCDANIEL K, Meng F, Wu N, Sato K, et al
    Forkhead box A2 regulated biliary heterogeneity and senescence during cholestatic liver injury.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28831.
    PubMed     Text format     Abstract available


  52. KAMINSKY P, Preiss J, Sasatomi E, Gerber DA, et al
    Biliary Adenofibroma: A Rare Hepatic Lesion with Malignant Features.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28818.
    PubMed     Text format    


  53. FIOROTTO R, Villani A, Kourtidis A, Scirpo R, et al
    CFTR controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity.
    Hepatology. 2016 Sep 15. doi: 10.1002/hep.28817.
    PubMed     Text format     Abstract available


    August 2016
  54. OKABE H, Yang J, Sylakowski K, Yovchev M, et al
    Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28774.
    PubMed     Text format     Abstract available


  55. WANG J, Xie C, Pan S, Liang Y, et al
    NDRG2 Inhibits Human Cholangiocarcinoma Progression and Is Regulated by LIF/MicroRNA-181c Negative feedback Pathway.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28781.
    PubMed     Text format     Abstract available


  56. GONZALES E, Taylor SA, Davit-Spraul A, Thebaut A, et al
    MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28779.
    PubMed     Text format     Abstract available


  57. SAPISOCHIN G, Facciuto M, Rubbia-Brandt L, Marti J, et al
    Liver transplantation for "very early" intrahepatic cholangiocarcinoma. international retrospective study supporting a prospective assessment.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28744.
    PubMed     Text format     Abstract available


    July 2016
  58. LI L, Piontek K, Ishida M, Fausther M, et al
    Extracellular vesicles carry miR-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28735.
    PubMed     Text format     Abstract available


  59. MARINELLI RA, Marrone J
    Aquaporin Gene Therapy for Cholestasis.
    Hepatology. 2016 Jul 26. doi: 10.1002/hep.28734.
    PubMed     Text format    


  60. KOPPE C, Verheugd P, Gautheron J, Reisinger F, et al
    IKKalpha/beta control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator RIPK1.
    Hepatology. 2016 Jul 11. doi: 10.1002/hep.28723.
    PubMed     Text format     Abstract available


  61. VERGANI D, Mieli-Vergani G
    Mouse model of primary biliary cholangitis with a striking female predominance: A new powerful research tool.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28718.
    PubMed     Text format    


    June 2016
  62. XU Y, Li F, Zalzala M, Xu J, et al
    FXR Activation Increases Reverse Cholesterol Transport by Modulating Bile Acid Composition and Cholesterol Absorption.
    Hepatology. 2016 Jun 30. doi: 10.1002/hep.28712.
    PubMed     Text format     Abstract available


  63. ARAB JP, Karpen SJ, Dawson PA, Arrese M, et al
    Bile acids & nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
    Hepatology. 2016 Jun 30. doi: 10.1002/hep.28709.
    PubMed     Text format     Abstract available


  64. DONEPUDI AC, Boehme S, Li F, Chiang JY, et al
    G protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28707.
    PubMed     Text format     Abstract available


  65. JONES H, Hargrove L, Kennedy L, Meng F, et al
    Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2-/- mice.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28704.
    PubMed     Text format     Abstract available


  66. WALESKY C, Goessling W
    Nature and Nurture - Environmental Toxins and Biliary Atresia.
    Hepatology. 2016 Jun 28. doi: 10.1002/hep.28701.
    PubMed     Text format    


  67. ROSENCRANTZ RA, Huang T, Sonke PY, Tewari D, et al
    Autoimmune Sclerosing Cholangitis: An Atypical Association with Kawasaki Disease.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28694.
    PubMed     Text format    


  68. WAGNER M, Fickert P, Zollner G
    Secretin and cholestasis, two sides of a coin.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28687.
    PubMed     Text format    


  69. BESNARD A, Gautherot J, Julien B, Tebbi A, et al
    The P2X4 purinergic receptor impacts liver regeneration after partial hepatectomy in mice through the regulation of biliary homeostasis.
    Hepatology. 2016 Jun 15. doi: 10.1002/hep.28675.
    PubMed     Text format     Abstract available


    May 2016
  70. HAPPERTS S, Foucault A, Billiard JS, Nguyen B, et al
    Combined hepatocellular-cholangiocarcinoma in a patient with Abernethy malformation and Tetralogy of Fallot - A case report.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28656.
    PubMed     Text format    


  71. GROEN AK
    Unexpected cholesterol gallstones.
    Hepatology. 2016 May 17. doi: 10.1002/hep.28646.
    PubMed     Text format    


  72. HOFMANN AF
    Let the Bile Flow! 1.0.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28633.
    PubMed     Text format    


  73. BAE HR, Leung PS, Tsuneyama K, Valencia JC, et al
    Chronic Expression of Interferon Gamma Leads to Murine Autoimmune Cholangitis with a Female Predominance.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28641.
    PubMed     Text format     Abstract available


  74. DUFFY AG, Makarova-Rusher OV, Greten TF
    The case for immune-based approaches in biliary tract carcinoma.
    Hepatology. 2016 May 14. doi: 10.1002/hep.28635.
    PubMed     Text format     Abstract available


  75. BEZERRA JA
    MDR3 mutation analysis: A step closer to precision medicine.
    Hepatology. 2016;63:1421-3.
    PubMed     Text format    


  76. LIASKOU E, Klemsdal Henriksen EK, Holm K, Kaveh F, et al
    High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.
    Hepatology. 2016;63:1608-19.
    PubMed     Text format     Abstract available


    April 2016
  77. TRADTRANTIP L, Verkman AS
    Aquaporin gene therapy for disorders of cholestasis?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28623.
    PubMed     Text format    


  78. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Text format     Abstract available


  79. BAGANTE F, Clark Gamblin T, Pawlik TM
    Cholangiocarcinoma Risk Factors and the Potential Role of Aspirin.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28613.
    PubMed     Text format    


  80. BERASAIN C, Fernandez-Barrena MG, Avila MA
    New molecular interactions of c-Myc in cholangiocarcinoma may open new therapeutic opportunities.
    Hepatology. 2016 Apr 21. doi: 10.1002/hep.28607.
    PubMed     Text format    


  81. REID LM
    Stem/progenitor cells and reprogramming (plasticity) mechanisms in liver, biliary tree and pancreas.
    Hepatology. 2016 Apr 21. doi: 10.1002/hep.28606.
    PubMed     Text format     Abstract available


  82. ZHAO X, Lorent K, Wilkins B, Marchione DM, et al
    Glutathione antioxidant pathway activity and reserve determine toxicity and specificity of the biliary toxin biliatresone in zebrafish.
    Hepatology. 2016 Apr 21. doi: 10.1002/hep.28603.
    PubMed     Text format     Abstract available


  83. WAISBOURD-ZINMAN O, Koh H, Tsai S, Lavrut PM, et al
    The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis via decreased glutathione and SOX17.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28599.
    PubMed     Text format     Abstract available


  84. TABIBIAN JH, Abu Dayyeh BK, Gores GJ, Levy MJ, et al
    A novel, minimally invasive technique for management of peristomal varices.
    Hepatology. 2016;63:1398-400.
    PubMed     Text format    


    March 2016
  85. DOORENSPLEET ME, Hubers LM, Culver EL, Maillette de Buy Wenniger LJ, et al
    IgG4+ B-Cell Receptor Clones Distinguish IgG4-Related Disease from Primary Sclerosing Cholangitis and Biliary/Pancreatic Malignancies.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28568.
    PubMed     Text format     Abstract available


  86. WANG HH, Li X, Patel SB, Wang DQ, et al
    Evidence that the ABCG5/G8-independent pathway plays a determinant role in cholesterol gallstone formation in mice.
    Hepatology. 2016 Mar 25. doi: 10.1002/hep.28570.
    PubMed     Text format     Abstract available


  87. MARRONE J, Soria LR, Danielli M, Lehmann GL, et al
    Hepatic Gene Transfer of Human Aquaporin-1 Improves Bile Salt Secretory Failure in Rats with Estrogen-Induced Cholestasis.
    Hepatology. 2016 Mar 21. doi: 10.1002/hep.28564.
    PubMed     Text format     Abstract available


  88. CHANG JC, Go S, de Waart DR, Munoz-Garrido P, et al
    Soluble adenylyl cyclase regulates bile salt-induced apoptosis in human cholangiocytes.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28550.
    PubMed     Text format     Abstract available


  89. ALVARO D, Gaudio E
    Biliary tree stem cell subpopulations.
    Hepatology. 2016 Mar 12. doi: 10.1002/hep.28546.
    PubMed     Text format    


  90. FRIEDRICH K, Smit M, Brune M, Giese T, et al
    CD14 is associated with biliary stricture formation.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28543.
    PubMed     Text format     Abstract available


  91. YANG H, Liu T, Wang J, Li TW, et al
    Deregulated methionine adenosyltransferase alpha1, c-myc and maf proteins interplay promotes cholangiocarcinoma growth in mice and humans.
    Hepatology. 2016 Mar 11. doi: 10.1002/hep.28541.
    PubMed     Text format     Abstract available


  92. CHOI J, Ghoz HM, Peeraphatdit T, Baichoo E, et al
    Risk Factors for Cholangiocarcinoma: Aspirin-use and the Risk of Cholangiocarcinoma.
    Hepatology. 2016 Mar 3. doi: 10.1002/hep.28529.
    PubMed     Text format     Abstract available


    February 2016
  93. ANANTHANARAYANAN M
    A novel long non-coding RNA (lncRNA) regulating Cholesterol and Bile acid homeostasis: A new kid on the block and a potential Therapeutic Target?
    Hepatology. 2016 Feb 29. doi: 10.1002/hep.28525.
    PubMed     Text format    


  94. DE WAART DR, Naik J, Utsunomiya KS, Duijst S, et al
    ATP11C targets basolateral bile salt transporter proteins in mouse central hepatocytes.
    Hepatology. 2016 Feb 29. doi: 10.1002/hep.28522.
    PubMed     Text format     Abstract available


  95. TANIMIZU N, Kaneko K, Itoh T, Ichinohe N, et al
    Intrahepatic bile ducts are developed through formation of homogeneous continuous luminal network and its dynamic rearrangement.
    Hepatology. 2016 Feb 29. doi: 10.1002/hep.28521.
    PubMed     Text format     Abstract available


  96. LI L, Che L, Tharp KM, Park HM, et al
    Differential Requirement for de novo Lipogenesis in Cholangiocarcinoma and Hepatocellular Carcinoma of Mice and Humans.
    Hepatology. 2016 Feb 22. doi: 10.1002/hep.28508.
    PubMed     Text format     Abstract available


  97. GUAN L, Zhang L, Gong Z, Hou X, et al
    FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance via Keap1-Nrf2 signaling.
    Hepatology. 2016 Feb 9. doi: 10.1002/hep.28496.
    PubMed     Text format     Abstract available


  98. WU W, Patel A, Kyostila K, Lohi H, et al
    Genome-wide Association Study in Mice Identifies Loci Affecting Liver-related Phenotypes Including Sel1l Influencing Serum Bile Acids.
    Hepatology. 2016 Feb 9. doi: 10.1002/hep.28495.
    PubMed     Text format     Abstract available


  99. OIKAWA T
    Cancer Stem Cells and Their Cellular Origins in Primary Liver and Biliary Tract Cancers.
    Hepatology. 2016 Feb 5. doi: 10.1002/hep.28485.
    PubMed     Text format     Abstract available


  100. HUPPERT SS
    A faithful JAGGED1 haploinsufficiency mouse model of arteriohepatic dysplasia (Alagille syndrome) after all.
    Hepatology. 2016;63:365-7.
    PubMed     Text format    


    January 2016
  101. TRIVEDI PJ, Weston CJ, Webb GJ, Newsome PN, et al
    Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-) ) knockout mice is strain specific.
    Hepatology. 2016;63:346.
    PubMed     Text format    


  102. KRONES E, Erwa W, Trauner M, Fickert P, et al
    Reply.
    Hepatology. 2016;63:346-7.
    PubMed     Text format    


    December 2015
  103. RIZVI S, Gores GJ
    Cholangiocarcinoma (CCA).
    Hepatology. 2015 Dec 15. doi: 10.1002/hep.28401.
    PubMed     Text format    


  104. LOCATELLI L, Cadamuro M, Spirli C, Fiorotto R, et al
    Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28382.
    PubMed     Text format     Abstract available


  105. EKSTEEN B
    Predicting risk in Primary Biliary Cholangitis.
    Hepatology. 2015 Dec 5. doi: 10.1002/hep.28377.
    PubMed     Text format    


    November 2015
  106. VARTAK N, Damle-Vartak A, Richter B, Dirsch O, et al
    Cholestasis-induced adaptive remodeling of interlobular bile ducts.
    Hepatology. 2015 Nov 26. doi: 10.1002/hep.28373.
    PubMed     Text format     Abstract available


  107. DAWSON PA
    Toxic Bile and Sclerosing Cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28363.
    PubMed     Text format    


  108. REYES H
    Sulfated progesterone metabolites in the pathogenesis of intrahepatic cholestasis of pregnancy: Another loop in the ascending spiral of medical knowledge.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28365.
    PubMed     Text format    


  109. JANSEN PL, Schaap FG
    Pandora's box opens for cholestatic liver disease.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28364.
    PubMed     Text format    


  110. HIRSCHFIELD GM, Gershwin ME, Strauss R, Mayo MJ, et al
    Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to Ursodeoxycholic Acid: a proof-of-concept study.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28359.
    PubMed     Text format     Abstract available


  111. LANZONI G, Cardinale V, Carpino G
    The hepatic, biliary and pancreatic network of stem/progenitor cells niches in humans: A new reference frame for disease and regeneration.
    Hepatology. 2015 Nov 2. doi: 10.1002/hep.28326.
    PubMed     Text format     Abstract available


  112. KUMTA NA, DeRoche K, Kahaleh M
    Temoporfin photodynamic therapy in advanced hilar ductal carcinoma: A promising endoscopic modality.
    Hepatology. 2015;62:1342-3.
    PubMed     Text format    


    October 2015
  113. YOKOMORI H, Yamazaki H, Oda M
    Freshwater clam extract supplement induced acute cholestasis.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28320.
    PubMed     Text format    


  114. STINDT J, Kluge S, Droge C, Keitel V, et al
    Bile Salt Export Pump-reactive Antibodies Form a Polyclonal, Multi-inhibitory Response in Antibody-induced BSEP Deficiency.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28311.
    PubMed     Text format     Abstract available


  115. LI Q, Kresge C, Bugde A, Lamphere M, et al
    Regulation of mechanosensitive biliary epithelial transport by the Epithelial Na Channel, ENaC.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28301.
    PubMed     Text format     Abstract available


  116. DELAUNAY JL, Durand-Schneider AM, Dossier C, Falguieres T, et al
    A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3.
    Hepatology. 2015 Oct 17. doi: 10.1002/hep.28300.
    PubMed     Text format     Abstract available


  117. REYES H
    What have we learned about Intrahepatic Cholestasis of Pregnancy?
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28295.
    PubMed     Text format    


  118. PENG ZW, Ikenaga N, Liu SB, Sverdlov DY, et al
    Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis and tumorigenesis.
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28274.
    PubMed     Text format     Abstract available


  119. LI Z, Feng J, Sun X
    Hypomethylation and hypohydroxymethylation of DNA in hepatocellular carcinoma and cholangiocarcinoma.
    Hepatology. 2015 Oct 5. doi: 10.1002/hep.28272.
    PubMed     Text format    


  120. ABU-HAYYEH S, Ovadia C, Lieu T, Jensen DD, et al
    Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum.
    Hepatology. 2015 Oct 1. doi: 10.1002/hep.28265.
    PubMed     Text format     Abstract available


    September 2015
  121. ZHOU M, Marc Learned R, Rossi SJ, DePaoli AM, et al
    Engineered FGF19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28257.
    PubMed     Text format     Abstract available


  122. PONSIOEN CY, Chapman RW, Chazouilleres O, Hirschfield GM, et al
    Surrogate endpoints for clinical trials in primary sclerosing cholangitis; review and results from an International PSC Study Group consensus process.
    Hepatology. 2015 Sep 29. doi: 10.1002/hep.28256.
    PubMed     Text format     Abstract available


  123. KOHLI R, Setchell KD
    Let the Bile Flow!
    Hepatology. 2015 Sep 22. doi: 10.1002/hep.28244.
    PubMed     Text format    


  124. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    Hepatology. 2015 Sep 15. doi: 10.1002/hep.28140.
    PubMed     Text format    


  125. GIOVANNONI R, Villanueva A
    Circulating tumor cells and cholangiocarcinoma.
    Hepatology. 2015 Sep 11. doi: 10.1002/hep.28152.
    PubMed     Text format    


  126. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
    Hepatology. 2015 Sep 4. doi: 10.1002/hep.28149.
    PubMed     Text format     Abstract available


  127. LEDERER A, Herrmann P, Seehofer D, Dietel M, et al
    Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients.
    Hepatology. 2015;62:841-50.
    PubMed     Text format     Abstract available


    August 2015
  128. SPIRLI C, Villani A, Mariotti V, Fabris L, et al
    Post-Translational Regulation of Polycystin-2 Protein Expression as a Novel Mechanism of Cholangiocyte Reaction and Repair from Biliary Damage.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28138.
    PubMed     Text format     Abstract available


  129. MARSCHALL HU, Backhed F
    Could gut microbiota protect against sclerosing cholangitis?
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28135.
    PubMed     Text format    


  130. TRIVEDI PJ, Corpechot C, Pares A, Hirschfield GM, et al
    Risk Stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.
    Hepatology. 2015 Aug 20. doi: 10.1002/hep.28128.
    PubMed     Text format     Abstract available


  131. SHIMODA S, Hisamoto S, Harada K, Iwasaka S, et al
    Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28122.
    PubMed     Text format     Abstract available


  132. THAKURDAS SM, Lopez MF, Kakuda S, Fernandez-Valdivia R, et al
    Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi).
    Hepatology. 2015 Aug 1. doi: 10.1002/hep.28024.
    PubMed     Text format     Abstract available


  133. THOMPSON RJ, Bull LN
    Treating genetic disease: Expanding the options.
    Hepatology. 2015;62:349-51.
    PubMed     Text format    


    July 2015
  134. CARBONE M, Sharp SJ, Flack S, Paximadas D, et al
    The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28017.
    PubMed     Text format     Abstract available


  135. SCIRPO R, Fiorotto R, Villani A, Amenduni M, et al
    Stimulation of nuclear receptor PPAR-gamma limits NF-kB-dependent inflammation in mouse cystic fibrosis biliary epithelium.
    Hepatology. 2015 Jul 21. doi: 10.1002/hep.28000.
    PubMed     Text format     Abstract available


  136. MARTI P, Stein C, Blumer T, Abraham Y, et al
    YAP promotes proliferation, chemoresistance and angiogenesis in human cholangiocarcinoma via TEAD transcription factors.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27992.
    PubMed     Text format     Abstract available


  137. MIETHKE AG, Zhang W, Simmons J, Taylor A, et al
    Pharmacological inhibition of ASBT changes bile composition and blocks progression of sclerosing cholangitis in mdr2 knockout mice.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27973.
    PubMed     Text format     Abstract available


  138. LI XY, Bai MJ, Chen LJ, Xu JL, et al
    Issue in statistical strategy in case-control study.
    Hepatology. 2015;62:320.
    PubMed     Text format    


  139. ALEKSANDROVA K, Pischon T
    Reply.
    Hepatology. 2015;62:320-1.
    PubMed     Text format    


    June 2015
  140. CHIANG JY
    Negative feedback regulation of bile acid metabolism: impact on liver metabolism and diseases.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27964.
    PubMed     Text format    


  141. CARULLI L, Gabbi C, Bertolotti M
    Bile acids and non-alcoholic fatty liver disease: An intriguing relationship.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27963.
    PubMed     Text format    


  142. HYLEMON P, Nagahashi M, Takabe K, Zhou H, et al
    Sphingosine-1-phosphate receptor 2 and conjugated bile acids: Key players in hepatic lipid metabolism.
    Hepatology. 2015 Jun 29. doi: 10.1002/hep.27961.
    PubMed     Text format    


  143. BARBIER-TORRES L, Beraza N, Fernandez-Tussy P, Lopitz-Otsoa F, et al
    Histone Deacetylase 4 promotes cholestatic liver injury in the absence of Prohibitin-1.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27959.
    PubMed     Text format     Abstract available


  144. LI M, Mennone A, Soroka CJ, Hagey LR, et al
    NHERF-1 knockout mice have an attenuated hepatic inflammatory response and are protected from cholestatic liver injury.
    Hepatology. 2015 Jun 25. doi: 10.1002/hep.27956.
    PubMed     Text format     Abstract available


  145. YANG JD, Campion MB, Liu MC, Chaiteerakij R, et al
    Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma.
    Hepatology. 2015 Jun 19. doi: 10.1002/hep.27944.
    PubMed     Text format     Abstract available


  146. TABIBIAN JH, O'Hara SP, Trussoni CE, Tietz PS, et al
    Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.
    Hepatology. 2015 Jun 4. doi: 10.1002/hep.27927.
    PubMed     Text format     Abstract available


  147. BERGASA NV
    The pruritus of cholestasis: facts.
    Hepatology. 2015;61:2114.
    PubMed     Text format    


    May 2015
  148. WAGNER A, Denzer UW, Neureiter D, Kiesslich T, et al
    Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study.
    Hepatology. 2015 May 20. doi: 10.1002/hep.27905.
    PubMed     Text format     Abstract available


  149. KUMAR S
    Cholestatic Liver Injury secondary to Artemisinin.
    Hepatology. 2015 May 16. doi: 10.1002/hep.27900.
    PubMed     Text format    


    April 2015
  150. SCHRAMM C, Wahl I, Lohse AW
    Reply.
    Hepatology. 2015;61:1435.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: